Marpa Minds Expands Spravato® Therapy Access Across Westchester and Rockland Counties

REMS-certified psychiatric clinic strengthens FDA-approved esketamine program for adults with treatment-resistant depression at White Plains and Suffern, NY

WHITE PLAINS, NY, UNITED STATES, September 2, 2026 /EINPresswire.com/ -- Marpa Minds, a REMS-certified outpatient psychiatric clinic with locations in White Plains and Suffern, NY, today announced expanded access to FDA-approved Spravato^® (esketamine) therapy for adults living with treatment-resistant depression across Westchester and Rockland counties.

The expansion strengthens Marpa Minds' specialized program for patients whose depression has not responded to traditional antidepressants — combining comprehensive psychiatric evaluations, insurance verification and prior authorization support, and medically supervised treatment sessions delivered under the FDA's Spravato REMS program.

As more patients and referring providers turn to evidence-based options beyond conventional antidepressant therapy, Marpa Minds has built a structured clinical program grounded in psychiatric expertise, individualized treatment planning, and ongoing patient support at every stage of care.

Why Specialized Spravato^® Therapy Matters for Treatment-Resistant Depression
Spravato^® (esketamine) is the first and only FDA-approved nasal spray for adults with treatment-resistant depression. As of January 2025, Spravato^® is FDA-approved for use either as a standalone treatment or alongside an oral antidepressant — expanding the range of patients who may benefit from esketamine therapy.

Spravato^® therapy isn't a treatment that can simply be added to an existing care plan. Identifying appropriate candidates requires a comprehensive psychiatric evaluation, review of previous treatment history, medical screening, and ongoing clinical oversight throughout the treatment course. Delivering FDA-approved esketamine also requires meeting specific REMS protocols designed to support patient safety and continuity of care.

That's where a specialized program becomes essential. Patients at Marpa Minds receive coordinated support at every stage:
1.Comprehensive psychiatric evaluations to determine whether Spravato^® therapy is clinically appropriate
2.Insurance verification and prior authorization handled by the Marpa Minds team before treatment begins
3.Medically supervised treatment sessions delivered under FDA REMS requirements at REMS-certified locations
4.Ongoing follow-up and treatment planning based on each patient's response and long-term goals

The Marpa Minds clinical team tailors treatment recommendations to each patient's symptoms, history, and mental health goals — rather than following a one-size-fits-all pathway.

Clinical Leadership Behind Marpa Minds' Spravato^® Program
As one of the leading mental health clinics in Westchester and Rockland counties, Marpa Minds brings psychiatric expertise, advanced depression treatment, and coordinated patient support together under one outpatient program.

The clinical team is led by Dr. Benjamin Medrano, MD, Practice Owner and Medical Director — a board-certified psychiatrist with extensive experience in evidence-based psychiatric care and ketamine-assisted treatments. Supporting the program is Amy Della Rocca, MSN, MPH, PMHNP-BC, Clinical Director, who has overseen thousands of Spravato^® and ketamine treatment sessions, helping patients navigate every stage of care with clinical oversight and continuity.

The clinic's approach is reflected in the experiences of patients who have completed treatment:
"After the better part of a decade, I can finally feel again. It was Spravato!!" — Rhonda T., Elementary School Teacher
"I felt like I was drowning. Marpa Minds helped me find myself again." — S.F., Real Estate Attorney

Rather than focusing solely on treatment delivery, the team works closely with each patient to develop an individualized care plan, monitor progress, and determine the most appropriate path forward.

Making Specialized Depression Care More Accessible
Access to Spravato^® therapy doesn't begin on the day of treatment. For many patients, the process starts with understanding eligibility, reviewing previous treatment history, navigating insurance requirements, and determining whether FDA-approved esketamine therapy is the most appropriate next step.
Marpa Minds supports this process through comprehensive evaluations, insurance coordination, patient education, and ongoing clinical guidance — reducing the barriers that often delay access to specialized depression care. Patients also receive clear information about what to expect during treatment, including typical timelines for response and how progress is evaluated over time.

Serving Westchester, Rockland, and Bergen County NJ
With locations in White Plains and Suffern, NY, Marpa Minds serves patients throughout Westchester County, Rockland County, Bergen County (NJ), and surrounding communities — providing evaluations, medically supervised treatment, and ongoing clinical support under one coordinated program.
In addition to Spravato^® therapy, Marpa Minds offers IV and IM ketamine therapy, TMS (Transcranial Magnetic Stimulation) therapy, and IV nutrient therapy — allowing the clinical team to match, combine, or sequence treatments based on each patient's needs rather than fitting patients to a single treatment option.

Individuals interested in learning whether Spravato^® therapy for treatment-resistant depression may be appropriate for their condition can schedule a consultation with the Marpa Minds team by calling +1 (914) 577-7646 or visiting the website to learn more about the program.

Chesky Breuer
Marpa Minds
email us here
Visit us on social media:
LinkedIn
Instagram
Facebook
YouTube
Other